Phase 2 Study of Omalizumab in Oral Peanut Desensitization

Trial Profile

Phase 2 Study of Omalizumab in Oral Peanut Desensitization

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Food hypersensitivity; Peanut hypersensitivity
  • Focus Therapeutic Use
  • Acronyms PRROTECT
  • Most Recent Events

    • 20 Feb 2018 Planned End Date changed from 1 Oct 2017 to 1 Oct 2020.
    • 23 Oct 2016 New trial record
    • 05 Sep 2016 Primary endpoint has been met. (Ability to tolerate a 2000-mg peanut dose 6 weeks after withdrawal of study drug), as reported by an articl published in the Journal of Allergy and Clinical Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top